Patient-derived tumour xenografts as models for oncology drug development - Test2 - elhamkhani - TriplyDB

Patient-derived tumour xenografts as models for oncology drug development

Patient-derived tumour xenografts as models for oncology drug development

http://www.wikidata.org/entity/Q24604068

about

Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic review Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX Bioengineering Models for Breast Cancer Research An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts Current State of Animal (Mouse) Modeling in Melanoma Research Molecular and clinical implementations of ovarian cancer mouse avatar models Use of rodents as models of human diseases Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment The role of surgeons in building a personalized medicine program Early phase clinical trials to identify optimal dosing and safety One mouse, one patient paradigm: New avatars of personalized cancer therapy Contemporary murine models in preclinical astrocytoma drug development Current status and evolution of preclinical drug development models of epithelial ovarian cancer Label-free DNA imaging in vivo with stimulated Raman scattering microscopy.Influence of handling conditions on the establishment and propagation of head and neck cancer patient derived xenografts Preclinical mouse cancer models: a maze of opportunities and challenges.Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells Systems biology approaches for advancing the discovery of effective drug combinations A natural small molecule, catechol, induces c-Myc degradation by directly targeting ERK2 in lung cancer Stimulated Raman scattering microscopy: an emerging tool for drug discovery Patient-derived xenografts: a relevant preclinical model for drug development Anti-cancer effects of Gynostemma pentaphyllum (Thunb.) Makino (Jiaogulan)Pharmacogenetics and pharmacogenomics as tools in cancer therapy Organoid development in cancer genome discovery Prioritizing therapeutic targets using patient-derived xenograft models Imaging tumor metabolism using positron emission tomography From bench to bedside: lessons learned in translating preclinical studies in cancer drug development Xenograft tumors vascularized with murine blood vessels may overestimate the effect of anti-tumor drugs: a pilot study Establishment and characterization of 7 novel hepatocellular carcinoma cell lines from patient-derived tumor xenografts Integrated analysis of transcriptome in cancer patient-derived xenografts Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds In vivo photoacoustic tomography of EGFR overexpressed in hepatocellular carcinoma mouse xenograft.Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer.A bioengineered heterotypic stroma-cancer microenvironment model to study pancreatic ductal adenocarcinoma.Erlotinib inhibits growth of a patient-derived chordoma xenograft.The future of patient-derived tumor xenografts in cancer treatment.

P2860

Q21131727-CDEA5CAC-5746-43A7-B313-DD7C55DB17C2 Q26741651-ADDDDD7A-765C-49F9-A728-E9F51A4E25B3 Q26746524-01ACCEE8-064E-4228-8EE3-9E9B08071F4A Q26770495-B94E4BEA-1484-4250-AEA8-E7840304EF2F Q26772895-E290F547-0EF5-43A2-8260-6CB78ACBD90A Q26781652-57E7BDDE-188E-47D2-95E2-B472E18B6DC2 Q26786724-5585ACB8-DFEF-4390-B651-4DB48C1F9501 Q26822856-7B8F9B3F-A959-4957-BED1-4ABA8B8E5946 Q26829125-5788D656-6BEA-4BCB-AE48-013F05606F90 Q26849667-8224CE30-6311-4118-81C8-5B97B1CB1EB3 Q26865076-A2822E13-D6F6-454C-A9E5-FC3DE8F21078 Q27023342-6E3B6040-5B56-4A22-9473-C94C068A06C9 Q27026937-989761C4-27E7-4BC6-8005-0A08F55EF7B5 Q27028117-408A5438-47AE-4305-9657-66B0E4AD1A69 Q27318691-E82335F8-997C-4C5F-B536-022B0A6280B2 Q27321370-155CD7D5-D6A0-4F5B-B0ED-A64BBF36934A Q27322080-55FED839-530A-4635-B325-89D452EE5939 Q27324252-F9B369DE-E312-4B5D-AC22-2C3EC44B8741 Q27324821-475D4F7C-FE82-4906-9C34-CA810FBBE399 Q27347800-00B7DC45-0809-4809-B572-92B7099CFA8F Q27702922-38AF5CAA-89BB-40C7-9C68-379654C921FC Q27704839-BCDAA626-3B83-4A65-AA85-CEF35D76A0DD Q28067096-C6091494-7BFF-40A8-87A0-66514FB54559 Q28067191-322F7F99-946E-49C5-BAD0-CF2D9D95E6F9 Q28074630-9A408AE6-6EC2-471F-B591-9116A2E661AD Q28076200-E3439ADA-A1BB-454D-AF77-2523D131A75D Q28083032-08F7EBAE-DEB8-4C91-AAC5-24A24281F0F3 Q28083993-F64067BF-A214-473E-9AD9-7369898065F0 Q28085278-007C6F58-85AF-4989-A307-1D1754BC2C96 Q28533949-83293E04-0816-43E0-961D-DA22AAF107F8 Q28538185-E2A2F380-AD50-4E2E-B73B-F472277261CE Q28538581-C14359DD-97BD-4BD6-8C2D-C204ECBC6DA4 Q28547069-F8503D9F-9631-4A63-A546-8310EA53634B Q28552408-01DF8803-53AA-4685-9701-D8F8CE07D61F Q28598343-E5A06A38-71D8-4E33-B525-47F6F63FFF45 Q30372076-64E13E0A-06EF-419F-B3A8-5F310AEBF228 Q30423597-82A5E84F-CA82-4517-AEE9-519E23E505BF Q30557486-DC4CF586-98A3-4E25-AD71-68DAC905A380 Q33275026-98A8A957-DDB7-4E0B-9FCC-202FE6EBD598 Q33361578-BB09739E-6BD6-42F7-AF0B-AD40521ED14F

P2860

Patient-derived tumour xenografts as models for oncology drug development

http://www.wikidata.org/entity/Q24604068

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Patient-derived tumour xenografts as models for oncology drug development

@ast

Patient-derived tumour xenografts as models for oncology drug development

@en

Patient-derived tumour xenografts as models for oncology drug development

@nl

type

label

Patient-derived tumour xenografts as models for oncology drug development

@ast

Patient-derived tumour xenografts as models for oncology drug development

@en

Patient-derived tumour xenografts as models for oncology drug development

@nl

prefLabel

Patient-derived tumour xenografts as models for oncology drug development

@ast

Patient-derived tumour xenografts as models for oncology drug development

@en

Patient-derived tumour xenografts as models for oncology drug development

@nl

P1433

Q24604068-08444BC2-A189-47D8-8A78-565E4B9A32AB

P1476

Q24604068-92DE63ED-6370-421F-AD63-41BB4B4AE771

P2093

Q24604068-1394DE20-1F65-4296-B723-DFD71E13E036

Q24604068-14868231-9F85-436C-B906-0FD8380721B2

Q24604068-16570167-8B46-48CE-847D-DAE550718443

Q24604068-4DCAE539-AB55-41E7-B39A-B79C576BFE9B

Q24604068-6E854F35-9AC9-4AC3-BF55-9AFFB4737BF4

Q24604068-86C54603-0B42-4DC6-9458-9C095980FA11

Q24604068-A282C7FD-D258-40B4-97EE-BB8105EA4E92

Q24604068-D516C8D8-B65B-4815-A010-93033C2C35CC

P2860

Q24604068-00AE34F4-E916-448D-8991-EBF4577371C9

Q24604068-00AF4CF7-3082-4425-8D39-C43446E7BB43

Q24604068-0408B243-1539-4416-87C0-1FB2D3E41D56

Q24604068-08A01817-15CF-4F63-9FCF-4511211AC389

Q24604068-08F71AD5-D007-4D41-8382-948E8BE29CF5

Q24604068-0A2F7D80-7C16-4225-8E8C-613675B41EE2

Q24604068-0AE0E4EC-9390-4DA7-856C-6DFB61C3AC36

Q24604068-0C6EE637-9EC5-4BDF-A666-EF4EA4A07BE5

Q24604068-0D1E3EBD-2DB1-432F-BEB7-4BA75F17DEEE

Q24604068-10C161FF-6CB1-4FAC-8B5A-4C53D511D771

P2888

Q24604068-51259266-1595-4CAB-ABA2-133BA46D6FD8

P304

Q24604068-753A788B-1D76-4981-A4D0-25260DA0B258

P31

Q24604068-607BD476-01C2-49A4-ACDA-49050FFA1413

P3181

Q24604068-5FFA5E7E-DC4D-466B-BB0E-2989B8B90046

P356

Q24604068-72C2E772-A248-404E-B4DD-EE5213E5D77D

P407

Q24604068-B32F954F-6ACA-438A-95CB-D11E4F0DCDD2

P433

Q24604068-D2F84670-1213-4ACE-9CC7-EF5D414906F6

P478

Q24604068-B6E29C9D-64F1-48A7-A105-2AFE7629F7BB

P50

Q24604068-9E4E787F-D4BF-48DE-A77E-F046A3BA72F2

P577

Q24604068-F25D5C86-4455-4735-816C-D9B17DF1C3D5

P6179

Q24604068-BB9419C0-C6AD-452E-8FFB-5E95F1BAB204

P698

Q24604068-94D7CE36-841C-4524-9C7E-3C32B5337343

P921

Q24604068-07F71D54-34A0-4F88-B466-F64D0E1265A4

Q24604068-59C71851-D222-48E7-9B8B-41D4FB80ECD2

P932

Q24604068-189042C4-A8E3-4603-9B45-443442081D2A

P3181

P356

NRCLINONC.2012.61

P1433

Nature Reviews Clinical Oncology

P1476

Patient-derived tumour xenografts as models for oncology drug development

@en

P2093

Antonio Jimeno

http://www.w3.org/2001/XMLSchema#string

Colin D Weekes

http://www.w3.org/2001/XMLSchema#string

John J Arcaroli

http://www.w3.org/2001/XMLSchema#string

John J Tentler

http://www.w3.org/2001/XMLSchema#string

S Gail Eckhardt

http://www.w3.org/2001/XMLSchema#string

Stephen Leong

http://www.w3.org/2001/XMLSchema#string

Todd M Pitts

http://www.w3.org/2001/XMLSchema#string

Wells A Messersmith

http://www.w3.org/2001/XMLSchema#string

P2860

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

Identification of cells initiating human melanomas

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro

Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene

Phenotypic characterization of human colorectal cancer stem cells

Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma.

P2888

nrclinonc.2012.61

P304

338-350

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

414131

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NRCLINONC.2012.61

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-04-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1013064241

http://www.w3.org/2001/XMLSchema#string

P698

22508028

http://www.w3.org/2001/XMLSchema#string

P921

P932

3928688

http://www.w3.org/2001/XMLSchema#string